目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Gastroesophageal Reflux Disease (GERD)
4.2.2 Rising Acceptance of Novel Drug Delivery Systems
4.3 Market Restraints
4.3.1 Increasing Use of Generic Products
4.3.2 Side Effects Related to Proton Pump Inhibitors
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 OTC (Over-the-counter) Drugs
5.1.1.1 Omeprazole
5.1.1.2 Lansoprazole
5.1.1.3 Esomeprazole
5.1.1.4 Other OTC Drugs
5.1.2 Prescription Drugs
5.1.2.1 Rabeprazole
5.1.2.2 Dexlansoprazole
5.1.2.3 Pantoprazole
5.1.2.4 Other Prescription Drugs
5.2 Geography
5.2.1 North America
5.2.1.1 United States (By Drug Type)
5.2.1.2 Canada (By Drug Type)
5.2.1.3 Mexico (By Drug Type)
5.2.2 Europe
5.2.2.1 Germany (By Drug Type)
5.2.2.2 United Kingdom (By Drug Type)
5.2.2.3 France (By Drug Type)
5.2.2.4 Italy (By Drug Type)
5.2.2.5 Spain (By Drug Type)
5.2.2.6 Rest of Europe (By Drug Type)
5.2.3 Asia-Pacific
5.2.3.1 China (By Drug Type)
5.2.3.2 Japan (By Drug Type)
5.2.3.3 India (By Drug Type)
5.2.3.4 Australia (By Drug Type)
5.2.3.5 South Korea (By Drug Type)
5.2.3.6 Rest of Asia-Pacific (By Drug Type)
5.2.4 Middle-East and Africa
5.2.4.1 GCC (By Drug Type)
5.2.4.2 South Africa (By Drug Type)
5.2.4.3 Rest of Middle-East and Africa (By Drug Type)
5.2.5 South America
5.2.5.1 Brazil (By Drug Type)
5.2.5.2 Argentina (By Drug Type)
5.2.5.3 Rest of South America (By Drug Type)

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca
6.1.2 Bayer AG
6.1.3 Cadila Pharmaceuticals
6.1.4 Eli Lilly and Company
6.1.5 Eisai Inc.
6.1.6 GlaxoSmithKline PLC
6.1.7 Johnson & Johnson
6.1.8 Pfizer Inc.
6.1.9 Santarus Inc.
6.1.10 Takeda Pharmaceuticals
6.1.11 Eisai Pharmaceuticals India Pvt. Ltd
6.1.12 Wyeth LLC
6.1.13 Sanofi SA
6.1.14 Perrigo Company PLC
6.1.15 Dr. Reddy's Laboratories
6.1.16 Aralez Pharmaceuticals Inc.
6.1.17 Redhill Pharma Limited
6.1.18 Cipla Limited
6.1.19 Changzhou Siyao Pharmaceuticals
6.1.20 Yangzhou Pharmaceutical

7 MARKET OPPORTUNITIES AND FUTURE TRENDS